NCT07675785 PfSPZ-LARC2 Vaccine(Sanaria) Malaria Vaccines Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07675785—PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07675785 is a hot trial to watch
Malaria Vaccines is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07675785 is notable because it tests PfSPZ-LARC2 Vaccine(Sanaria) in a Phase 2 design with Incidence of local AEs as a primary decision variable. The wider PatSnap topic query returned 334 trial records and 514 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07675785 |
| Official title | PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | PfSPZ-LARC2 Vaccine(Sanaria) |
| Sponsor | Sanaria, Inc. |
| Geography | Mali |
| Enrollment | 300 |
| Primary endpoint | Incidence of local AEs |
| Endpoint time frame | Day 1 to Day 35 |
| Primary completion | 2028-07-15 |
| Study completion | 2030-04-01 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Incidence of local AEs—determines what uncertainty this study can resolve. The reported time frame is Day 1 to Day 35. Enrollment of 300 participants and geography in Mali shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- Exposure-Response Evaluation of IV Artesunate in Children With Severe Malaria (Phase 4): -; Maximum Concentration (Cmax) of Dihydroartemisinin (DHA)(Median) = 4,361.09 ug/L (Full Range, 3,488.88 - 4,368.38); -.
- Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure (Phase 4): Number of Patients Experiencing P. Vivax Recurrence = 48 Participants ; -; Number of Patients Experiencing P. Vivax Recurrence = 11 Participants ; -; -.
- Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial (Phase 3): AE(drug related) = 16.0 Pts ; AE(drug related) = 24.0 Pts ; AE(drug related) = 13.0 Pts .
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: PfSPZ-LARC2 Vaccine(Sanaria) (Phase 2; target not reported).
Company & Deal Intelligence context: Sanaria, Inc. — http://www.sanaria.com.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07675785 is a focused lens on Malaria Vaccines development. Its value will be determined by whether PfSPZ-LARC2 Vaccine(Sanaria) can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
